Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving ...

Blujepa is approved to treat females 12 and older with uncomplicated urinary tract infections, or UTIs. About half of all ...

Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes.

This antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...

Blujepa, the brand name for gepotidacin ... According to GSK, 16 million women in the U.S. struggle with UTIs each year, and ...

If you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially ...

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...

In two studies with over 3,000 women and children who had a mild UTI, Blujepa, a pill taken twice a day for five days, worked as well as or better than nitrofurantoin, a common UTI antibiotic.

A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...

The Food and Drug Administration (FDA) has approved a new drug for treating urinary tract infections, the first such drug ...

The U.S. Food and Drug Administration has granted approval to a new antibiotic to treat urinary tract infections in women and ...